Copenhagen 2016 Registration Programme Exhibitor Information Virtual Exhibition Satellite Meetings Glaucoma Day 2016 Hotel Star Alliance
title

10 - 14 Sept. 2016, Bella Center, Copenhagen, Denmark

This Meeting has been awarded 27 CME credits

 

escrs app advert yo advert

Pharmacological PCO-prophylaxis using EGFR-inhibitor erlotinib soaked IOLs as a drug carrier

Search Title by author or title

Session Details

Session Title: Presented Poster Session: PCO

Session Date/Time: Sunday 11/09/2016 | 09:30-11:00

Paper Time: 10:10

Venue: Poster Village: Pod 1

First Author: : A.Kueres GERMANY

Co Author(s): :    C. Wertheimer   A. Wolf   C. Priglinger   S. Priglinger   K. Eibl-Lindner  

Abstract Details

Purpose:

A common complication after cataract surgery is posterior capsule opacification (PCO). EGF-Receptor selective inhibitor Erlotinib has been proven to mitigate the cellular basis of PCO in vitro and in an ex-vivo human capsular bag model. Yet there is no proper possibility to apply Erlotinib directly to the lens capsule. This study examines Erlotinib-presoaked intraocular lenses (IOL) as a drug carrier against PCO.

Setting:

Laboratory for Molceular Cell Biology, University Eye Hospital, LMU Munich, Germany

Methods:

Erlotinib soaked IOLs were examined in an in-vitro anterior segment model as described by Gotoh et al. in 2007. The anterior segment model imitates the human capsular bag situation in-vitro, whereas cell proliferation and migration under the IOL can be observed and measured. Furthermore development of PCO was observed in a human capsular bag model in 24 eyes of 12 human donors. Methods for securing human capsular bags were performed analogously to modern cataract surgery and were approved by the local ethics committee.

Results:

Compared to unsoaked control IOLs, Erlotinib modified IOLs were able to reduce growth of PCO significantly in both the Gotoh anterior segment model (p=0.14) and the human capsular bag in vitro. Cell growth on cell culture inserts was reduced by Erlotinib modified IOLs by 63%. No difference between different IOL materials was shown (p=0.24). Capsular bags with modified IOLs reached confluency after 7.22d in control (95% CI: 6.22d-8.22d) versus 14.17d with Erlotinib soaked IOLs (95%CI: 12.90d -15.43d)

Conclusions:

In the forseeable future pharmacologically modified IOLs could reduce development of PCO and are therefore an encouraging attempt to improve efficacy of cataract surgery.

Financial Disclosure:

NONE

Back to previous